Skip to main content
Erschienen in: Rheumatology International 8/2012

01.08.2012 | Original Article

G109T polymorphism of SLC22A12 gene is associated with serum uric acid level, but not with metabolic syndrome

verfasst von: Won Cheoul Jang, Youn Hyoung Nam, Young Chang Ahn, Su Min Park, Il Kyu Yoon, Jung-Yoon Choe, Sung-Hoon Park, Minyoung Her, Seong-Kyu Kim

Erschienen in: Rheumatology International | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

SLC22A12 gene, encoding urate transport 1, has been known to be responsible to urate metabolism. This study sought to determine the association between the novel G109T polymorphism in SLC22A12 with serum uric acid and the development of metabolic syndrome in Korean male subjects. A total of 132 healthy male subjects were enrolled in this study. Metabolic syndrome was determined using the modified guidelines for metabolic syndrome proposed by the National Cholesterol Education Program’s Third Adult Treatment Panel. Genotyping for the SLC22A12 gene was assessed using denaturing high-performance liquid chromatography analysis. Serum uric acid and fractional excretion of uric acid (FEUA) from blood and urine samples were measured. Frequencies of the 109GG, 109GT, and 109TT genotypes were 57.6, 38.6, and 3.8%, respectively. Serum uric acid levels and FEUAs were significantly different among the three genotypes of the G109T polymorphism (P = 0.035 and P = 0.033, respectively). In addition, subjects of genotypes with the T allele had lower uric acid levels and higher FEUAs compared to those with the 109GG genotype (P = 0.007 and P = 0.031, respectively). The G109T polymorphism of the SLC22A12 gene has no association with metabolic syndrome. However, a number of metabolic syndrome components were related to serum uric acid level (r = 0.285, P = 0.001) and also significantly different between genotype with and without T allele (P = 0.008). The novel G109T polymorphism of the SLC22A12 gene is related to serum uric acid level, but not to the development of metabolic syndrome.
Literatur
1.
Zurück zum Zitat Becker BF (1993) Towards the physiological function of uric acid. Free Radic Biol Med 14:615–631PubMedCrossRef Becker BF (1993) Towards the physiological function of uric acid. Free Radic Biol Med 14:615–631PubMedCrossRef
2.
Zurück zum Zitat Hediger MA, Johnson RJ, Miyazaki H et al (2005) Molecular physiology of urate transport. Physiology 20:125–133PubMedCrossRef Hediger MA, Johnson RJ, Miyazaki H et al (2005) Molecular physiology of urate transport. Physiology 20:125–133PubMedCrossRef
3.
Zurück zum Zitat Pérez-Ruiz F, Calabozo M, Erauskin GG et al (2002) Renal under excretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 15:610–613CrossRef Pérez-Ruiz F, Calabozo M, Erauskin GG et al (2002) Renal under excretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 15:610–613CrossRef
4.
Zurück zum Zitat Terkeltaub R, Bushinsky DA, Becker MA (2006) Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther 8(Suppl 1):S4PubMedCrossRef Terkeltaub R, Bushinsky DA, Becker MA (2006) Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther 8(Suppl 1):S4PubMedCrossRef
5.
Zurück zum Zitat Enomoto A, Kimura H, Chairoungdua A et al (2002) Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:447–452PubMed Enomoto A, Kimura H, Chairoungdua A et al (2002) Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:447–452PubMed
6.
Zurück zum Zitat Hosoyamada M, Ichida K, Enomoto A et al (2004) Function and localization of urate transporter 1 in mouse kidney. J Am Soc Nephrol 15:261–268PubMedCrossRef Hosoyamada M, Ichida K, Enomoto A et al (2004) Function and localization of urate transporter 1 in mouse kidney. J Am Soc Nephrol 15:261–268PubMedCrossRef
7.
Zurück zum Zitat Ichida K, Hosoyamada M, Hisatome I et al (2004) Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 15:164–173PubMedCrossRef Ichida K, Hosoyamada M, Hisatome I et al (2004) Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 15:164–173PubMedCrossRef
8.
Zurück zum Zitat Iwai N, Mino Y, Hosoyamada M et al (2004) A high prevalence of renal hypouricemia caused by inactive SLC22A12 in Japanese. Kidney Int 66:935–944PubMedCrossRef Iwai N, Mino Y, Hosoyamada M et al (2004) A high prevalence of renal hypouricemia caused by inactive SLC22A12 in Japanese. Kidney Int 66:935–944PubMedCrossRef
9.
Zurück zum Zitat Jang WC, Nam YH, Park SM et al (2008) T6092C polymorphism of SLC22A12 gene is associated with serum uric acid concentrations in Korean male subjects. Clin Chim Acta 398:140–144PubMedCrossRef Jang WC, Nam YH, Park SM et al (2008) T6092C polymorphism of SLC22A12 gene is associated with serum uric acid concentrations in Korean male subjects. Clin Chim Acta 398:140–144PubMedCrossRef
10.
Zurück zum Zitat Shima Y, Teruya K, Ohta H (2006) Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese. Life Sci 79:2234–2237PubMedCrossRef Shima Y, Teruya K, Ohta H (2006) Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese. Life Sci 79:2234–2237PubMedCrossRef
11.
Zurück zum Zitat Taniguchi A, Urano W, Yamanaka M et al (2005) A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout. Arthritis Rheum 52:2576–2577PubMedCrossRef Taniguchi A, Urano W, Yamanaka M et al (2005) A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout. Arthritis Rheum 52:2576–2577PubMedCrossRef
12.
Zurück zum Zitat Vázquez-Mellado J, Jiménez-Vaca AL, Cuevas-Covarrubias S et al (2007) Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout. Rheumatology (Oxford) 46:215–219CrossRef Vázquez-Mellado J, Jiménez-Vaca AL, Cuevas-Covarrubias S et al (2007) Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout. Rheumatology (Oxford) 46:215–219CrossRef
13.
Zurück zum Zitat Culleton BF (2001) Uric acid and cardiovascular disease: a renal–cardiac relationship? Curr Opin Nephrol Hypertens 10:371–375PubMedCrossRef Culleton BF (2001) Uric acid and cardiovascular disease: a renal–cardiac relationship? Curr Opin Nephrol Hypertens 10:371–375PubMedCrossRef
14.
Zurück zum Zitat Forman JP, Choi H, Curhan GC (2009) Uric acid and insulin sensitivity and risk of incident hypertension. Arch Intern Med 169:155–162PubMedCrossRef Forman JP, Choi H, Curhan GC (2009) Uric acid and insulin sensitivity and risk of incident hypertension. Arch Intern Med 169:155–162PubMedCrossRef
15.
Zurück zum Zitat Culleton BF, Larson MG, Kannel WB et al (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131:7–13PubMed Culleton BF, Larson MG, Kannel WB et al (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131:7–13PubMed
16.
Zurück zum Zitat Ioachimescu AG, Brennan DM, Hoar BM et al (2008) Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 58:623–630PubMedCrossRef Ioachimescu AG, Brennan DM, Hoar BM et al (2008) Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 58:623–630PubMedCrossRef
17.
Zurück zum Zitat Bieber JD, Terkeltaub RA (2004) Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 50:2400–2414PubMedCrossRef Bieber JD, Terkeltaub RA (2004) Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 50:2400–2414PubMedCrossRef
18.
Zurück zum Zitat Cirillo P, Sato W, Reungjui S et al (2006) Uric acid, the metabolic syndrome, and renal disease. J Am Soc Nephrol 17:S165–S168PubMedCrossRef Cirillo P, Sato W, Reungjui S et al (2006) Uric acid, the metabolic syndrome, and renal disease. J Am Soc Nephrol 17:S165–S168PubMedCrossRef
19.
Zurück zum Zitat Rathmann W, Haastert B, Icks A et al (2007) Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: the CARDIA study. Eur J Epidemiol 22:439–445PubMedCrossRef Rathmann W, Haastert B, Icks A et al (2007) Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: the CARDIA study. Eur J Epidemiol 22:439–445PubMedCrossRef
20.
Zurück zum Zitat Nakagawa T, Hu H, Zharikov S et al (2006) A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290:F625–F631PubMedCrossRef Nakagawa T, Hu H, Zharikov S et al (2006) A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290:F625–F631PubMedCrossRef
21.
Zurück zum Zitat Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–97 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–97
22.
Zurück zum Zitat World Health Organisation, Western Pacific Region, The Asia-Pacific Perspective (2000) Redefining obesity and its treatment, WHO/IASO/IOTF 2000 World Health Organisation, Western Pacific Region, The Asia-Pacific Perspective (2000) Redefining obesity and its treatment, WHO/IASO/IOTF 2000
23.
Zurück zum Zitat Lipkowitz MS, Leal-Pinto E, Rappoport JZ et al (2001) Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest 107:1103–1115PubMedCrossRef Lipkowitz MS, Leal-Pinto E, Rappoport JZ et al (2001) Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest 107:1103–1115PubMedCrossRef
24.
Zurück zum Zitat Graessler J, Graessler A, Unger S et al (2006) Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 54:292–300PubMedCrossRef Graessler J, Graessler A, Unger S et al (2006) Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 54:292–300PubMedCrossRef
25.
Zurück zum Zitat Munan L, Kelly A, Petitclerc C (1976) Population serum urate levels and their correlates. The Sherbrooke regional study. Am J Epidemiol 103:369–382PubMed Munan L, Kelly A, Petitclerc C (1976) Population serum urate levels and their correlates. The Sherbrooke regional study. Am J Epidemiol 103:369–382PubMed
26.
Zurück zum Zitat Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 283:2404–2410PubMedCrossRef Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 283:2404–2410PubMedCrossRef
27.
Zurück zum Zitat Choe JY, Park SH, Kim JY et al (2008) Change in serum uric acid between baseline and 1-year follow-up and its associated factors in male subjects. Clin Rheumatol 27:483–489PubMedCrossRef Choe JY, Park SH, Kim JY et al (2008) Change in serum uric acid between baseline and 1-year follow-up and its associated factors in male subjects. Clin Rheumatol 27:483–489PubMedCrossRef
28.
29.
Zurück zum Zitat Rho YH, Woo JH, Choi SJ et al (2008) Association between serum uric acid and the Adult Treatment Panel III-defined metabolic syndrome: results from a single hospital database. Metabolism 57:71–76PubMedCrossRef Rho YH, Woo JH, Choi SJ et al (2008) Association between serum uric acid and the Adult Treatment Panel III-defined metabolic syndrome: results from a single hospital database. Metabolism 57:71–76PubMedCrossRef
30.
Zurück zum Zitat Lin JD, Chiou WK, Chang HY et al (2007) Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid. Metabolism 56:751–756PubMedCrossRef Lin JD, Chiou WK, Chang HY et al (2007) Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid. Metabolism 56:751–756PubMedCrossRef
Metadaten
Titel
G109T polymorphism of SLC22A12 gene is associated with serum uric acid level, but not with metabolic syndrome
verfasst von
Won Cheoul Jang
Youn Hyoung Nam
Young Chang Ahn
Su Min Park
Il Kyu Yoon
Jung-Yoon Choe
Sung-Hoon Park
Minyoung Her
Seong-Kyu Kim
Publikationsdatum
01.08.2012
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 8/2012
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-1952-5

Weitere Artikel der Ausgabe 8/2012

Rheumatology International 8/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.